We demonstrated that in about 60% of AITL/PTLC-NOS patients identical pathogenic TET2 and/or DNMT3A mutations were shared between AITL/PTCL-NOS and CH found in the BM or PB. This evidence concerns the gene DNMT3A and angioimmunoblastic T-cell lymphoma.